After its Myloral and Colloral oral tolerance products failed to show statistically significant benefits to treat multiple sclerosis and rheumatoid arthritis, Autoimmune Inc. was forced to shut down operations. Nevertheless, the company is working to provide some returns to its investors, holding on to rights to products in clinical trials funded by others and raising cash by licensing its intellectual property.

Last week AIMM (Lexington, Mass.) licensed patent applications relating to the treatment of Alzheimer's disease (AD) to Elan Corp. plc for up to $7 million over three years (see B3).